Three all-oral shortened regimens have noninferior efficacy compared with standard therapy for fluoroquinolone-suscep ...

Scientists have discovered three powerful new drug regimens that offer more effective treatment for tuberculosis—bringing ...

Now, in a major step forward, an international clinical trial has found three new safe and effective drug regimens for ...

Tuberculosis remains one of the deadliest infectious diseases worldwide, with drug-resistant strains posing a significant ...

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs to treat tuberculosis and enhanced funding now ...

New options make TB treatment faster, safer, and more accessible. A major breakthrough in tuberculosis treatment has emerged: ...

Tuberculosis remains one of the top infectious disease killers worldwide , a challenge amplified by drug-resistant forms of the disease. Now, in a ...

Rifampin-resistant tuberculosis has traditionally been treated with 18-to-24-month regimens, but shorter, all-oral regimens may offer efficacious alternatives. New research findings are summarized ...